Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M701 intrapleural infusion in advanced non-small cell lung cancer with malignant pleural effusion
CTR20221949Phase 2Active
- Sponsor
- YZY Biopharma
- Start
- Dec 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of M701 in malignant pleural effusion (MPE) and non-small cell lung cancer (NSCLC) (11 arms), sponsored by YZY Biopharma. Primary endpoint: Safety and tolerability of multiple ascending intrapleural doses of M701; determination of RP2D and suitable dosing frequency. Started Dec 2022; status: active.
02
Drugs
M701
03
Conditions
malignant pleural effusion (MPE)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221949.